Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.17 - $2.49 $451 - $961
386 Added 2270.59%
403 $0
Q1 2024

Nov 05, 2024

SELL
$1.13 - $2.23 $436 - $860
-386 Reduced 95.78%
17 $0
Q1 2024

May 15, 2024

SELL
$1.13 - $2.23 $280 - $553
-248 Reduced 93.58%
17 $0
Q4 2023

Feb 14, 2024

BUY
$1.03 - $1.45 $272 - $384
265 New
265 $0
Q2 2023

Aug 14, 2023

BUY
$1.47 - $1.86 $51 - $65
35 Added 318.18%
46 $0
Q1 2023

May 15, 2023

BUY
$1.46 - $1.83 $16 - $20
11 New
11 $0
Q3 2022

Nov 14, 2022

SELL
$2.72 - $5.19 $84 - $160
-31 Reduced 15.5%
169 $0
Q3 2021

Nov 15, 2021

SELL
$6.74 - $8.02 $3,006 - $3,576
-446 Reduced 69.04%
200 $1,000
Q2 2021

Aug 16, 2021

BUY
$7.6 - $10.28 $4,909 - $6,640
646 New
646 $6,000

Others Institutions Holding NXTC

About NextCure, Inc.


  • Ticker NXTC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,748,800
  • Market Cap $36.4M
  • Description
  • NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...
More about NXTC
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.